

## Magnetic Resonance Therapy Improves Clinical Phenotype and EEG Alpha Power in Posttraumatic Stress Disorder

Alexander Taghva,<sup>1,2,\*</sup> Robert Silvetz,<sup>3</sup> Alex Ring,<sup>1,3</sup> Keun-young A. Kim,<sup>2</sup> Kevin T. Murphy,<sup>4</sup> Charles Y. Liu,<sup>1,5</sup> and Yi Jin<sup>1,3,6</sup>

<sup>1</sup>Center for Neurorestoration, University of Southern California, Los Angeles, USA

<sup>2</sup>Orange County Neurosurgical Associates, Mission Viejo, USA

<sup>3</sup>Newport Brain Research Laboratory, Newport Beach, USA

<sup>4</sup>Department of Radiation Oncology, University of California, San Diego, La Jolla, USA

<sup>5</sup>Department of Neurosurgery, University of Southern California, Los Angeles, USA

<sup>6</sup>Department of Psychiatry and Human Behavior, University of California, Irvine, USA

\*Corresponding author: Alexander Taghva, Orange County Neurosurgical Associates, Mission Viejo, USA. Tel: +1-9493887190, E-mail: alextaghva@gmail.com

Received 2015 February 23; Revised 2015 May 10; Accepted 2015 June 28

### Abstract

**Background:** Posttraumatic stress disorder (PTSD) is a disabling and prevalent psychiatric disorder with limited effective treatment options. In addition to the clinical features of the disease, pathologic changes in the electroencephalogram (EEG), including decreased alpha power, have been reported.

**Objectives:** To determine if magnetic brain stimulation can induce normalization of EEG abnormalities and improve clinical symptoms in PTSD in a preliminary, open-label evaluation.

**Materials and Methods:** We reviewed prospectively-collected data on 21 veterans that were consecutively-treated for PTSD. Magnetic resonance therapy (MRT) was administered for two weeks at treatment frequencies based on frequency-domain analysis of each patient's dominant alpha-band EEG frequencies and resting heart rate. Patients were evaluated on the PTSD checklist (PCL-M) and pre- and post-treatment EEGs before and after MRT.

**Results:** Of the 21 patients who initiated therapy, 16 completed treatment. Clinical improvements on the PCL-M were seen in these 16 patients, with an average pre-treatment score of 54.9 and post-treatment score of 31.8 ( $P < 0.001$ ). In addition, relative global EEG alpha-band (8-13 Hz) power increased from 32.0 to 38.5 percent ( $P = 0.013$ ), and EEG delta-band (1-4 Hz) power decreased from 32.3 percent to 26.8 percent ( $P = 0.028$ ).

**Conclusions:** These open-label data show trends toward normalization of EEG and concomitant clinical improvement using magnetic stimulation for PTSD.

**Keywords:** Magnetic Resonance Therapy, Posttraumatic Stress Disorder, Electroencephalogram, Neuromodulation, Transcranial Magnetic Stimulation, Prefrontal Cortex

### 1. Background

Posttraumatic stress disorder (PTSD) is a disabling, prevalent, and difficult to treat psychiatric disorder characterized by response to a traumatic event that involves "intense fear, helplessness, or horror" (1). Cardinal diagnostic features of PTSD in patients who have experienced a definite traumatic event are 1) recurrent, intrusive recollections of the event, 2) avoidance of stimuli associated with trauma or generalized emotional numbing, 3) symptoms of hyperarousal including insomnia, and 4) functional distress or impairment in social, occupational, or other important areas (1). In addition, patients often have deficits in cognitive function, including deficits in attention, memory, and learning (2, 3). Lifetime prevalence of PTSD is estimated at 5 to 8 percent of men and 10 to 14 percent of women, making it the fourth most common psychiatric disorder (4-6). Despite pharmacologic

and psychological therapies, 74 percent of patients have symptoms lasting over 6 months, and up to 30 percent of patients with PTSD will not recover from this illness at 10 years following diagnosis, and few spontaneous recoveries occur after 12 months (7, 8).

Neuroimaging studies consistently implicate the ventromedial prefrontal cortex (vmPFC) and amygdala as affected limbic circuit nodes in the pathogenesis of PTSD (9-15). In addition, electroencephalogram (EEG) analyses of PTSD-afflicted patients suggest abnormalities including globally decreased alpha power (16). Neuromodulation, including transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS), has been suggested as a potential treatment option for the disorder (17). In animal studies of neuromodulation, high frequency stimulation of the amygdala in a rat model of PTSD ameliorates PTSD-associ-



ated behaviors (18). A recent human clinical study suggests some improvement in PTSD patients with a short course of repetitive TMS (19). In addition, magnetic stimulation of the brain has been shown to induce frequency changes on EEG. (For a review, please see Thut and Pascual-Leone (20)).

Magnetic resonance therapy (MRT) is a variation of transcranial magnetic stimulation where treatment frequencies are derived from patient's dominant alpha-band frequency and resting heart rate.

## 2. Objectives

In this study, MRT was utilized in the treatment of PTSD. Clinical results were followed with PTSD checklist (PCL-M), a validated, 17-item, self-report metric for PTSD symptomatology (21). Clinical improvements in PTSD checklist (PCL-M), as well as relative increases in post-treatment EEG alpha (8 - 13 Hz) power and relative decreases in delta power (1 - 4 Hz) were observed. This work suggests clinical improvements as well as trends of EEG toward normalization with magnetic stimulation of the brain in PTSD.

## 3. Materials and Methods

A retrospective review of prospectively collected data was performed at the Newport brain research laboratories (NBRL) and brain treatment center (BTC) Clinic. From June 2013 to March 2014, 21 veterans (ages 26 - 42 years, mean 32 years, all male) with prior diagnosis of PTSD underwent treatment with magnetic resonance therapy (MRT). Inclusion criteria included a prior diagnosis of PTSD by a psychiatrist, history of traumatic event, and symptoms from each of the three diagnostic categories (recurrence, avoidance, and arousal). Patients were identified by clinician referral to the clinic and underwent clinical and psychometric evaluation at the center prior to treatment. PCL-M score of greater than 44 was used as a guide (22, 23), however, two patients with borderline PCL-M scores were treated based on clinical assessment. Exclusion criteria included history of seizure disorder, history of intracranial lesion, history of intracranial implant, prior transcranial magnetic therapy, and inability to adhere to the treatment schedule. Informed consent was obtained for all patients and IRB approval obtained. Pre-treatment EEG as well as post-treatment EEG were obtained. In addition, patients were asked to complete the PCL-M prior to and following 2 weeks of treatment. PCL-MM is a 17-item, self-report metric for PTSD symptomatology, which maps to DSM criteria and correlates strongly with the Clinician Administered PTSD Scale (CAPS) (21, 24-26). Each item can be scored from 1 (most severe) to 5 (least severe). Therefore, 17 is the lowest (least symptomatic) and 85 is the highest possible score (most symptomatic). Cutoff scores suggested for PTSD diagnosis based on PCL-M range from 30 - 50 (21, 27-30). An initial five-day trial of stimulation was performed to assess efficacy and tolerability, at which point, patients could elect to continue with a full-course of treatment (2 weeks).

An awake, eyes-closed baseline EEG was recorded using

standard 19-lead electrode setup. EEG and ECG time-series data were converted to frequency-domain using Fast Fourier Transform (FFT) (Mathematica, Wolfram, Champaign, Illinois). Dominant alpha-frequency is selected based on the frequency with highest power in the 8 - 13 Hz range as described previously in the treatment of other psychiatric disorders (31-33). Higher harmonic frequencies (5th to 10th) of the electrocardiogram resting heart rate were then calculated. The ECG harmonic frequency nearest the dominant alpha frequency was chosen as treatment frequency for MRT. For example, in a patient with a dominant alpha frequency of 9.7 Hz and resting heart rate of 72 bpm (1.2 Hz), the 8th harmonic of the heart rate ( $8 \times 1.2 \text{ Hz} = 9.6 \text{ Hz}$ ) was chosen as the treatment frequency. Stimulation intensity was at 80% of motor threshold, and stimulation was delivered to the region of highest EEG irregularity when compared to a normative database with regard to bandwidth powers at a specific location. In this study, treatment location was prefrontal cortices.

MRT was administered via MCF-B65 Butterfly coil (Magventure Inc, Denmark) to the prefrontal cortices at the above-assigned frequency. Magnetic pulses were delivered in 6 second trains with a 30 second intertrain interval, and 30 trains per session. Treatment was performed five times per week for two weeks.


Pre- and post-treatment EEG analyses were performed by assessing relative bandwidth power in the delta (1 - 4 Hz), theta (4 - 8 Hz), alpha (8 - 13 Hz), and beta (13 - 30 Hz). Pre- and post-treatment relative powers as well as pre- and post-treatment PCL-M were analyzed using paired, two-tailed, Student's T-test.

## 4. Results


Of the 21 patients who initiated treatment, 16 completed therapy (76 percent). Of the five patients that did not continue therapy, they cited inability to commit to daily treatment (3 patients) or that they did not feel improvement after initial treatment (2 patients). Of the 16 patients who completed therapy, average initial PCL-M was 54.9, range 41 - 75, and average post-treatment PCL-M was 31.8, range 17 - 47 (pre- to post-treatment,  $P < 0.001$ , Figure 1). This yields an average decrease of 23.2 points (average change 42 percent), and 16 of 16 patients had some decrease in PCL-M (range 9 - 39 points).

Relative EEG alpha power from pre- to post-treatment increased in 11 of 16 patients (68.8 percent) from an average of 32.0 percent to 38.5 percent (20.2 percent increase,  $P = 0.013$ , Figure 2). Relative EEG delta decreased in 10 of 16 patients (62.3 percent), and changed from 32.3 percent to 26.8 percent (16 percent decrease,  $P = 0.028$ ). Relative theta-band and beta-band EEG changes appeared minor and were statistically insignificant (theta, 23.4 percent to 22.4 percent,  $P = 0.545$ ; beta, 12.2 percent to 12.3 percent,  $P = 0.961$ ). An example EEG pre- and post-treatment is shown in Figure 3. No adverse events (seizures, neurologic deficit, worsening of pretreatment condition) were reported.






**Figure 1.** Pre- and Post-MRT PCL-M Scores, Average Initial PCL-M Was 54.9, Range 41 - 75, and Average Post-Treatment PCL-M Was 31.8, Range 17 - 47 (Pre- to Post-Treatment,  $P < 0.01$ )



**Figure 2.** Pre- and Post-MRT EEG Band Power, Relative EEG Alpha Power From Pre- to Post-Treatment Increased From 32.0 Percent to 38.5 Percent ( $P = 0.013$ ), Relative EEG Delta Decreased From 32.3 Percent to 26.8 Percent ( $P = 0.028$ ). Relative Theta-Band and Beta-Band EEG Changes Were Minor and Statistically Insignificant (Theta, 23.4 Percent to 22.4 Percent,  $P = 0.545$ ; Beta, 12.2 Percent to 12.3 Percent,  $P = 0.961$ ).



**Figure 3.** Sample Pre- and Post-MRT EEG Spectral Analysis. Rows Indicate Channels From Standard 19-Lead EEG With ECG Power Spectra in Bottom Row. (A) Pre-Treatment EEG With Increased Relative Slow-Wave (Delta, Theta) Power Relative to Alpha Power. (B) Post-Treatment EEG With Decreased Slow-Wave Power and Increased Relative Alpha Power.



## 5. Discussion

PTSD is a prevalent, disabling illness with limited efficacy of available treatment options (7). Neuromodulatory therapies, including magnetic stimulation, have shown some initial promise in the treatment of this disorder (19, 34, 35). Prior works on repetitive transcranial magnetic stimulation suggest improvement with PTSD, though these have focused on low-frequency magnetic stimulation (1 Hz) (19, 34). Cohen in 2004 showed greater clinical benefit with high-frequency stimulation (10 Hz) than with low-frequency stimulation (1 Hz) (35). This clinical difference may be due to “high-frequency” stimulation being nearer to alpha frequencies (8 - 13 Hz). In the treatment paradigm of this paper, a patient’s dominant alpha frequency and heartbeat harmonic are used to determine stimulation frequency. Neuroimaging studies indicate that the primary neurocircuitry dysfunction in PTSD lies in the ventromedial prefrontal cortices (9-14). There is precedent for treatment of frontal circuit disorders with magnetic stimulation, including the treatment of major depressive disorder (MDD), with positive clinical results (36, 37). Frontocortical circuitry defects are also thought to belie the clinical dysfunction in MDD (38). Furthermore, magnetic stimulation of the brain has been shown to create EEG changes that persist beyond the duration of treatment (20), but to our knowledge, no study has shown trends toward normalization in EEG power spectra concomitant with clinical improvement using these modalities.

In this study, MRT of the brain is used as a form of “non-invasive neuromodulation.” 21 veterans with prior diagnosis of PTSD were treated with MRT. Treatment frequency was selected based on dominant alpha frequency on pretreatment EEG. Of the 21 patients, 16 completed the study and had improvement in clinical metrics (PCL-M). Therefore, based on an intention-to-treat analysis, 16 of 21 patients (76 percent) had at least modest improvements in their PTSD symptoms. On average, these improvements amounted to approximately 1.4 points per item on the PCL-M questionnaire. In addition, global alpha power increased on EEG with relative decreases in delta-band power. Electrophysiology studies suggest alpha power is decreased in the PTSD population (16), so this may indicate amelioration of this defect.

With that in mind, it is notable that while 16 patients had improvement of clinical symptoms, only 11 had increases in global EEG alpha. Therefore, more sophisticated analyses including localized versus global EEG band power, EEG coherence, or information theoretic analyses such as EEG entropy may be required to correlate with this treatment effect. Aberrations in neural oscillatory activity are present in many neuropsychiatric disorders including movement disorders, schizophrenia, and Alzheimer’s disease (39). Subjective review of post-treatment EEGs in our population suggest synchronization of brain regions with regard to dominant alpha frequency post-MRT, and

we believe this effect requires further study and characterization. In addition, an incidental observation were self-reports from subjects of decreased substance use (tobacco, alcohol, and pain medications). This is a qualitative finding that may warrant further research and investigation in future studies.

Obvious study limitations here include lack of control arm, open-label design, lack of female participants, and lack of long-term treatment persistence data. Given these shortcomings, randomized, controlled, double-blinded studies are underway. Despite these shortcomings, these results show EEG trends toward normal as well as concomitant clinical improvements with MRT and suggest a role for non-invasive neuromodulation in the treatment of PTSD.

PTSD is a serious, prevalent, and disabling psychiatric illness that is often refractory to currently available treatments. Given the significant burden of this disease, there needs to be continued exploration for new treatment approaches, especially interventions that may be effective for those individuals refractory to existing treatments. The success of neuromodulation with other conditions marked by frontal lobe dysfunction makes it a potential treatment option for PTSD, especially given the well-described alterations in neurocircuitry evident in this condition. This study suggests that non-invasive neuromodulation magnetic resonance therapy may lead clinical improvements as well as a trend toward normalization of EEG pathophysiology in PTSD.

## Footnotes

**Authors’ Contribution:**Alexander Taghva, Robert Silvetz, and Yi Jin co-developed the idea of applying magnetic resonance therapy to PTSD and developed protocols regarding this. Alexander Taghva wrote the manuscript. Alex Ring, Alexander Taghva, Robert Silvetz performed data analysis, collection, and interpretation of results. Keun-young A. Kim, Kevin T. Murphy, and Charles Y. Liu provided editorial support. Yi Jin developed the basic principles regarding magnetic resonance therapy.

**Financial Disclosure:**Robert Silvetz, Yi Jin, and Alex Ring are employees and have equity interest in Newport Brain Research Laboratories, which administers magnetic resonance therapy.

**Funding/Support:**All funding was derived internally. No external sources of funding were utilized.

## References

1. American Psychiatric Association. Task Force on DSM-IV. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR*. 4 ed. Washington, DC: American Psychiatric Association; 2000. p. 943.
2. Vasterling JJ, Brailey K, Constans JI, Sutker PB. Attention and memory dysfunction in posttraumatic stress disorder. *Neuropsychology*. 1998;**12**(1):125-33.
3. Vasterling JJ, Duke LM, Brailey K, Constans JI, Allain AJ, Sutker PB. Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. *Neuropsychology*. 2002;**16**(1):5-14.
4. Yehuda R. Post-traumatic stress disorder. *N Engl J Med*. 2002;**346**(2):108-14.



5. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1995;**52**(12):1048–60.
6. Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. *Arch Gen Psychiatry*. 1991;**48**(3):216–22.
7. Breslau N. Outcomes of posttraumatic stress disorder. *J Clin Psychiatry*. 2001;**62 Suppl 17**:55–9.
8. Cancro R. Mental health impact of September 11. *Mol Psychiatry*. 2004;**9**(12):1055–6.
9. Koh KK, Quon MJ, Han SH, Lee Y, Park JB, Kim SJ, et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. *Int J Cardiol*. 2011;**146**(3):319–25.
10. Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S, et al. Brain activation in PTSD in response to trauma-related stimuli. *Biol Psychiatry*. 1999;**45**(7):817–26.
11. Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M. Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. *Eur Arch Psychiatry Clin Neurosci*. 2002;**252**(2):68–75.
12. Shin LM, McNally RJ, Kosslyn SM, Thompson WL, Rauch SL, Alpert NM, et al. A positron emission tomographic study of symptom provocation in PTSD. *Ann NY Acad Sci*. 1997;**821**:521–3.
13. Rauch SL, Whalen PJ, Shin LM, McNerney SC, Macklin ML, Lasko NB, et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. *Biol Psychiatry*. 2000;**47**(9):769–76.
14. Koenigs M, Huey ED, Raymond V, Cheon B, Solomon J, Wassermann EM, et al. Focal brain damage protects against posttraumatic stress disorder in combat veterans. *Nat Neurosci*. 2008;**11**(2):232–7.
15. Shvil E, Rusch HL, Sullivan GM, Neria Y. Neural, psychophysiological, and behavioral markers of fear processing in PTSD: a review of the literature. *Curr Psychiatry Rep*. 2013;**15**(5):358.
16. Kemp AH, Griffiths K, Felmingham KL, Shankman SA, Drinkenburg W, Arns M, et al. Disorder specificity despite comorbidity: resting EEG alpha asymmetry in major depressive disorder and post-traumatic stress disorder. *Biol Psychol*. 2010;**85**(2):350–4.
17. Taghva A, Oluigbo C, Corrigan J, Rezai AR. Posttraumatic stress disorder: neurocircuitry and implications for potential deep brain stimulation. *Stereotact Funct Neurosurg*. 2013;**91**(4):207–19.
18. Langevin JP, De Salles AA, Kosoyan HP, Krahl SE. Deep brain stimulation of the amygdala alleviates post-traumatic stress disorder symptoms in a rat model. *J Psychiatr Res*. 2010;**44**(16):1241–5.
19. Watts BV, Landon B, Groft A, Young-Xu Y. A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. *Brain Stimul*. 2012;**5**(1):38–43.
20. Thut G, Pascual-Leone A. A review of combined TMS-EEG studies to characterize lasting effects of repetitive TMS and assess their usefulness in cognitive and clinical neuroscience. *Brain Topogr*. 2010;**22**(4):219–32.
21. Weathers FW, Litz BT, Herman DS, Huska JA, Keane TM. The PTSD Checklist (PCL): Reliability, validity, and diagnostic utility; 9th Annual Conference of the ISTSS; San Antonio. 1993.
22. Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD Checklist (PCL). *Behav Res Ther*. 1996;**34**(8):669–73.
23. Ventureyra VA, Yao SN, Cottraux J, Note I, De Mey-Guillard C. The validation of the Posttraumatic Stress Disorder Checklist Scale in posttraumatic stress disorder and nonclinical subjects. *Psychother Psychosom*. 2002;**71**(1):47–53.
24. Forbes D, Creamer M, Biddle D. The validity of the PTSD checklist as a measure of symptomatic change in combat-related PTSD. *Behav Res Ther*. 2001;**39**(8):977–86.
25. Monson CM, Gradus JL, Young-Xu Y, Schnurr PP, Price JL, Schumm JA. Change in posttraumatic stress disorder symptoms: do clinicians and patients agree? *Psychol Assess*. 2008;**20**(2):131–8.
26. Keen SM, Kutter CJ, Niles BL, Krinsley KE. Psychometric properties of PTSD Checklist in sample of male veterans. *J Rehabil Res Dev*. 2008;**45**(3):465–74.
27. Andrykowski MA, Cordova MJ, Studts JL, Miller TW. Posttraumatic stress disorder after treatment for breast cancer: prevalence of diagnosis and use of the PTSD Checklist-Civilian Version (PCL-C) as a screening instrument. *J Consult Clin Psychol*. 1998;**66**(3):586–90.
28. Cook JM, Elhai JD, Arean PA. Psychometric properties of the PTSD Checklist with older primary care patients. *J Trauma Stress*. 2005;**18**(4):371–6.
29. Dobie DJ, Kivlahan DR, Maynard C, Bush KR, McFall M, Epler AJ, et al. Screening for post-traumatic stress disorder in female Veteran's Affairs patients: validation of the PTSD checklist. *Gen Hosp Psychiatry*. 2002;**24**(6):367–74.
30. Yeager DE, Magruder KM, Knapp RG, Nicholas JS, Frueh BC. Performance characteristics of the posttraumatic stress disorder checklist and SPAN in Veterans Affairs primary care settings. *Gen Hosp Psychiatry*. 2007;**29**(4):294–301.
31. Jin Y, Phillips B. A pilot study of the use of EEG-based synchronized Transcranial Magnetic Stimulation (sTMS) for treatment of Major Depression. *BMC Psychiatry*. 2014;**14**:13.
32. Jin Y, Potkin SG, Kemp AS, Huerta ST, Alva G, Thai TM, et al. Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophrenia. *Schizophr Bull*. 2006;**32**(3):556–61.
33. Jin Y, Kemp AS, Huang Y, Thai TM, Liu Z, Xu W, et al. Alpha EEG guided TMS in schizophrenia. *Brain Stimul*. 2012;**5**(4):560–8.
34. Nam DH, Pae CU, Chae JH. Low-frequency, Repetitive Transcranial Magnetic Stimulation for the Treatment of Patients with Posttraumatic Stress Disorder: a Double-blind, Sham-controlled Study. *Clin Psychopharmacol Neurosci*. 2013;**11**(2):96–102.
35. Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. *Am J Psychiatry*. 2004;**161**(3):515–24.
36. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress Anxiety*. 2012;**29**(7):587–96.
37. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. *Psychopharmacol Bull*. 2009;**42**(2):5–38.
38. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. *Neuron*. 2005;**45**(5):651–60.
39. Schnitzler A, Gross J. Normal and pathological oscillatory communication in the brain. *Nat Rev Neurosci*. 2005;**6**(4):285–96.